🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Time for our debate: Melina Marmarelis , Penn Medicine, arguing for adjuvant treatment as the preferred treatment option for early stage lung cancer. #FoxChaseLungCME

Drs. Melina Marmarelis and Dr. Julie Brahmer go expert-a-expert on neoadjuvant vs adjuvant therapy in resectable NSCLC at #FoxChaseLungCME. Great that evolution in this space has afforded us the opportunity to even hold this discussion!

Our panel discussion about early stage lung cancer. Lots of variability in how we manage early stage disease.

Excited to share our new study nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow haniel.araujo and Minh Truong Do. Thankful to our patients. MD Anderson Cancer Center

Brief Report: Osimertinib Plus Capmatinib for Patients with MET-Altered EGFR NSCLC following progression “Cap/osi is an effective and reasonably well tolerated treatment for osimertinib-resistant EGFR-mutant NSCLC with MET alteration.” clinical-lung-cancer.com/article/S1525-…

For MET-alt osi refractory #NSCLC, our #realworld study found #Capmatinib + osi produced a durable response (mPFS ~18m). Big advance for #targeted therapy! Thank you Clinical Lung Cancer Melina Marmarelis Charu Aggarwal, MD, MPH, FASCO Lova Sun sciencedirect.com/science/articl…

Publication alert 🚨 : Penn researchers propose rules for determining lines of therapy from real-world data of patients with metastatic non-small cell #LungCancer treated with targeted therapies. Melina Marmarelis #NSCLC spr.ly/6011QxDx3

Dr. Melina Marmarelis returns to the #TexasLung25 stage to discuss mesothelioma in our session on rare thoracic tumors. Don’t miss this expert insight at the 2-day #CE-accredited conference. Explore the full agenda: hubs.la/Q0375FBc0

WHAT A WONDERFUL DISCUSSION! Discussing NUT Carcinoma and Mesothelioma with these amazing ladies Dr. Melina Marmarelis and Jia Luo, MD at #TTLC25 IASLC

Do you treat all patients with atypical EGFR mutations with the same TKI? Adam Barsouk MD presents our retrospective ATOMIC study at #TTLC IASLC suggesting that the type of atypical mutation should drive our TKI choice. Penn Medicine - Abramson Cancer Center Charu Aggarwal, MD, MPH, FASCO Corey Langer Awesome job! 👏🏻

Melina Marmarelis Adam Barsouk MD IASLC Penn Medicine - Abramson Cancer Center Charu Aggarwal, MD, MPH, FASCO Corey Langer Adam is on 🔥 🔥

After Dr. Heather Wakelee Keynote IASLC #TTLC25 with the amazing selfies and describing her journey, had to take this selfie with Melina Marmarelis Natalie Vokes who are amazing physicians/leaders and also colleagues on the ASCO 25 Lung Scientific program committee!

Surprise appearance by the other Dr Marmarelis (aka my dad) at #TTLC25 Wonderful to see colleagues (and family) in sunny CA! Thank you IASLC!

Out today in JTO & JTO CRR our case report detailing discordant IO response in biphasic diffuse pleural mesothelioma with identification of BRAF V600E and durable response to BRAF/MEK TKI. Highlights importance of NGS in this rare malignancy. jtocrr.org/article/S2666-…

These guys and gals are the best - lovely to work with my #lungcancer track at ASCO headquarters to help plan the #ASCO25 scientific meeting. Led by the fearless Rafeh Naqash, MD to keep us all in line! 😂

#PC3IatASCO: Melina Marmarelis, Charu Aggarwal, MD, MPH, FASCO & team used an EMR-based nudge for #NSCLC molecular testing at time of 1st post-operative visit. Findings showed the nudges increased rate of #moleculartesting in patients. #ASCO25 #LungCancer #LCSM ASCO meetings.asco.org/abstracts-pres…

Way to guarantee more traffic at your poster? Be next to Stephen V Liu, MD of course! 🤩✨⭐️ ASCO #ASCO25 @LCSM #TiP

Check out poster today! Penn Cancer Innovation Penn Medicine - Abramson Cancer Center Melina Marmarelis ASCO #ASCO25

The best thoracic/HN section! So grateful to work with each one of these fabulous individuals ASCO #ASCO25 Penn Medicine Penn Medicine - Abramson Cancer Center Penn Medicine MD

📣 #ASCO25: NeoADAURA trial in resectable EGFR-mutated NSCLC ➡️ Neoadj osimertinib ± chemo vs chemo alone 🎉 >90% completed surgery, >90% R0 ➡️ mPR: 57% (osi±chemo) vs 22% (chemo) ➡️ pCR: 17% vs 3% 🦾EFS HR 0.73 trend 👏🏽looking forward to oncological outcomes! #lcsm